Extrafine triple therapy in patients with asthma and persistent airflow limitation

The addition of a long-acting muscarinic antagonist (LAMA) is a recognised treatment option for patients whose asthma is uncontrolled with an inhaled corticosteroid (ICS) plus long-acting β2-agonist (LABA) combination [1]. The data supporting this recommendation were provided from studies in which the LAMA tiotropium was added to ICS/LABA combinations using separate inhalers [2, 3]. The use of separate inhalers, most often of different design, with contrasting instructions for use and dosing regimens is not only inconvenient for patients and healthcare providers who provide instruction on correct inhaler use but can also negatively impact treatment adherence and persistence and, therefore, outcomes [4–7].

Source: European Respiratory Journal - September 23, 2020 Category: Respiratory Medicine Authors: Singh, D., Virchow, J. C., Canonica, G. W., Vele, A., Kots, M., Georges, G., Papi, A. Tags: Original Articles: Research letters Source Type: research